Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Highnoon LaboratoriesKAR:HINOON -0.45%96 FCF Margin % is 4.18% as of Mar. 2026, which is 16% below its 10-year median of 4.98. GuruFocus rates KAR:HINOON with a GF Score™ of 96/100 and a GF Value™ of ₨1,019.72 (Fairly Valued). The stock has 3 warning signs investors should review. Among 962 Drug Manufacturers companies, Highnoon Laboratories ranks better than 60.71% on this metric.
The historical rank and industry rank for Highnoon Laboratories's FCF Margin % or its related term are showing as below:
KAR:HINOON'
s FCF Margin % Range Over the Past 10 Years
Min: -7.92 Med: 4.98 Max: 16.71
Current: 6.48
During the past 13 years, the highest FCF Margin % of Highnoon Laboratories was 16.71%. The lowest was -7.92%. And the median was 4.98%.
KAR:HINOON's FCF Margin % is ranked better than 60.71% of 962
companies
in the Drug Manufacturers industry
Industry Median: 2.585
vs KAR:HINOON: 6.48
Highnoon Laboratories FCF Margin % Related Terms
Highnoon Laboratories FCF Margin % Historical Data
* Premium members only.
The historical data trend for Highnoon Laboratories's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:HINOON vs LLY, JNJ, ABBV: FCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Highnoon Laboratories's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Highnoon Laboratories FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Highnoon Laboratories's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Highnoon Laboratories's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Highnoon Laboratories (KAR:HINOON) has a FCF Margin % of 4.18% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Highnoon Laboratories and its competitors. This is 16% below median its historical median of 4.98. According to the industry distribution chart, Highnoon Laboratories ranks #378 out of 962 companies in the Drug Manufacturers industry, placing it in the top 39.3%.
Is Highnoon Laboratories' FCF Margin % too high?
Highnoon Laboratories' current FCF Margin % of 4.18% is 16% below median its 10-year median of 4.98. The Drug Manufacturers industry median FCF Margin % is 2.59. Highnoon Laboratories' value of 4.18% is 61.7% above this industry median. Based on the distribution chart, Highnoon Laboratories ranks #378 out of 962 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Highnoon Laboratories has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Highnoon Laboratories' FCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Highnoon Laboratories ranks #378 out of 962 companies for FCF Margin %. This puts Highnoon Laboratories in the upper half of its industry. The industry median FCF Margin % is 2.59. Highnoon Laboratories' value of 4.18% is 61.7% above this benchmark. While the company's 10-year median is 4.98 vs. the industry median of 2.59, Highnoon Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.59, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Highnoon Laboratories's current FCF Margin % of 4.18% is 61.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Highnoon Laboratories and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Highnoon Laboratories's current FCF Margin % is 4.18%, which is 16% below median its own 10-year median of 4.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Highnoon Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Highnoon Laboratories (KAR:HINOON) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,019.72, compared to a current price of ₨961.21 — trading 5.7% below its estimated fair value. The current FCF Margin % is 4.18%, which is 16% below median its 10-year median of 4.98 and 61.7% above the Drug Manufacturers industry median of 2.59. Highnoon Laboratories' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Highnoon Laboratories (KAR:HINOON), the current FCF Margin % is 4.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Highnoon Laboratories (KAR:HINOON) Overvalued in 2026?
Based on GuruFocus' analysis, Highnoon Laboratories stock appears to be undervalued.
The current stock price of ₨961.21 is trading 5.7% below its estimated GF Value™ of ₨1,019.72.
GuruFocus considers Highnoon Laboratories to be Fairly Valued.
Key valuation signals for KAR:HINOON:
FCF Margin %: 4.18% (16% below median its 10-year median of 4.98)
GF Value™: ₨1,019.72 vs. price of ₨961.21 (5.7% below fair value)
Industry Position: 61.7% above the Drug Manufacturers median (#378 of 962)
No single metric tells the full story. See the KAR:HINOON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Highnoon Laboratories Ltd is a company engaged in the manufacture, import, sale, and marketing of pharmaceutical and allied consumer products. It focuses on the alimentary tract and metabolism, antihistamines, anti-infectives, cardiovascular, endocrine, hematology, musculoskeletal, nervous system, parasitology, respiratory, and urinary. Its products include AIRTAL (Aceclofenac); ARIA (ketotifen); ARTECXCIN, and artrodar (diacerein). Its other products include Asthavent, AXESOME, Bezisox, Betatec, and many more.
96GF Score
Get the complete analysis for KAR:HINOON
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:HINOON has been successfully added to your 
